Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revision Previous revision
Next revision
Previous revision
covid:unpublished [2020/06/02 13:55]
biogridadmin
covid:unpublished [2020/08/05 13:15] (current)
biogridadmin
Line 5: Line 5:
  
 **WARNING** - Please treat these papers with caution as they are preliminary reports that have not been peer-reviewed. They should not be regarded as conclusive, guide clinical practice/​health-related behavior, or be reported in news media as established information. **WARNING** - Please treat these papers with caution as they are preliminary reports that have not been peer-reviewed. They should not be regarded as conclusive, guide clinical practice/​health-related behavior, or be reported in news media as established information.
-  + 
-^  Custom ID  ^  DOI  ^  ​Author ​ ​^ ​Dataset ​ ^ +^  Custom ID  ^  DOI  ^  ​AUTHOR ​ ​^ ​DATASET ​ ^
-|  **888800000001** ​ |  **[[https://​doi.org/​10.1101/​2020.03.22.002386|10.1101/​2020.03.22.002386]]** ​ |  Gordon DE (2020) ​ | **[[https://​thebiogrid.org/​220839/​publication|A SARS-CoV-2-Human Protein-Protein Interaction Map Reveals Drug Targets and Potential Drug-Repurposing]]** ​ |+
 |  **888800000002** ​ |  **[[https://​doi.org/​10.1101/​2020.03.29.20041962|10.1101/​2020.03.29.20041962]]** ​ |  Gao T (2020) ​ | **[[https://​thebiogrid.org/​221112/​publication|Highly pathogenic coronavirus N protein aggravates lung injury by MASP-2-mediated complement over-activation]]** ​ | |  **888800000002** ​ |  **[[https://​doi.org/​10.1101/​2020.03.29.20041962|10.1101/​2020.03.29.20041962]]** ​ |  Gao T (2020) ​ | **[[https://​thebiogrid.org/​221112/​publication|Highly pathogenic coronavirus N protein aggravates lung injury by MASP-2-mediated complement over-activation]]** ​ |
-|  **888800000003** ​ |  **[[https://​doi.org/​10.1101/​2020.02.16.951723|10.1101/​2020.02.16.951723]]** ​ |  ​Xie L (2020) ​ | **[[https://​thebiogrid.org/​221178/​publication|SARS-CoV-2 and SARS-CoV Spike-RBD Structure and Receptor Binding Comparison and Potential Implications on Neutralizing Antibody and Vaccine Development]]** ​ |+|  **888800000003** ​ |  **[[https://​doi.org/​10.1101/​2020.02.16.951723|10.1101/​2020.02.16.951723]]** ​ |  ​Sun C (2020) ​ | **[[https://​thebiogrid.org/​221178/​publication|SARS-CoV-2 and SARS-CoV Spike-RBD Structure and Receptor Binding Comparison and Potential Implications on Neutralizing Antibody and Vaccine Development]]** ​ |
 |  **888800000004** ​ |  **[[https://​doi.org/​10.1101/​2020.03.16.994236|10.1101/​2020.03.16.994236]]** ​ |  Procko E (2020) ​ | **[[https://​thebiogrid.org/​221182/​publication|The sequence of human ACE2 is suboptimal for binding the S spike protein of SARS coronavirus 2]]**  | |  **888800000004** ​ |  **[[https://​doi.org/​10.1101/​2020.03.16.994236|10.1101/​2020.03.16.994236]]** ​ |  Procko E (2020) ​ | **[[https://​thebiogrid.org/​221182/​publication|The sequence of human ACE2 is suboptimal for binding the S spike protein of SARS coronavirus 2]]**  |
 |  **888800000005** ​ |  **[[https://​doi.org/​10.1101/​2020.03.14.988345|10.1101/​2020.03.14.988345]]** ​ |  Wang K (2020) ​ | **[[https://​thebiogrid.org/​221183/​publication|SARS-CoV-2 invades host cells via a novel route: CD147-spike protein]]** ​ | |  **888800000005** ​ |  **[[https://​doi.org/​10.1101/​2020.03.14.988345|10.1101/​2020.03.14.988345]]** ​ |  Wang K (2020) ​ | **[[https://​thebiogrid.org/​221183/​publication|SARS-CoV-2 invades host cells via a novel route: CD147-spike protein]]** ​ |
 |  **888800000006** ​ |  **[[https://​doi.org/​10.1101/​2020.02.17.951848|10.1101/​2020.02.17.951848]]** ​ |  Zhou Q (2020) ​ | **[[https://​thebiogrid.org/​221185/​publication|Structure of dimeric full-length human ACE2 in complex with B0AT1]]** ​ | |  **888800000006** ​ |  **[[https://​doi.org/​10.1101/​2020.02.17.951848|10.1101/​2020.02.17.951848]]** ​ |  Zhou Q (2020) ​ | **[[https://​thebiogrid.org/​221185/​publication|Structure of dimeric full-length human ACE2 in complex with B0AT1]]** ​ |
 +|  **888800000007** ​ |  **[[https://​doi.org/​10.1101/​2020.02.26.964882|10.1101/​2020.02.26.964882]]** ​ |  Jin Z (2020) ​ | **[[https://​thebiogrid.org/​221186/​publication|Structure of Mpro from COVID-19 virus and discovery of its inhibitors [DEPRECATED PUBLICATION]]]** ​ |
 |  **888800000008** ​ |  **[[https://​doi.org/​10.1101/​2020.03.29.013490|10.1101/​2020.03.29.013490]]** ​ |  Wang C (2020) ​ | **[[https://​thebiogrid.org/​221195/​publication|Lectin-like Intestinal Defensin Inhibits 2019-nCoV Spike binding to ACE2]]** ​ | |  **888800000008** ​ |  **[[https://​doi.org/​10.1101/​2020.03.29.013490|10.1101/​2020.03.29.013490]]** ​ |  Wang C (2020) ​ | **[[https://​thebiogrid.org/​221195/​publication|Lectin-like Intestinal Defensin Inhibits 2019-nCoV Spike binding to ACE2]]** ​ |
 |  **888800000009** ​ |  **[[https://​doi.org/​10.1101/​2020.03.25.996348|10.1101/​2020.03.25.996348]]** ​ |  Dai W (2020) ​ | **[[https://​thebiogrid.org/​221196/​publication|Structure-Based Design, Synthesis and Biological Evaluation of Peptidomimetic Aldehydes as a Novel Series of Antiviral Drug Candidates Targeting the SARS-CoV-2 Main Protease]]** ​ | |  **888800000009** ​ |  **[[https://​doi.org/​10.1101/​2020.03.25.996348|10.1101/​2020.03.25.996348]]** ​ |  Dai W (2020) ​ | **[[https://​thebiogrid.org/​221196/​publication|Structure-Based Design, Synthesis and Biological Evaluation of Peptidomimetic Aldehydes as a Novel Series of Antiviral Drug Candidates Targeting the SARS-CoV-2 Main Protease]]** ​ |
Line 19: Line 19:
 |  **888800000012** ​ |  **[[https://​doi.org/​10.1101/​2020.03.31.019216|10.1101/​2020.03.31.019216]]** ​ |  Liang Q (2020) ​ | **[[https://​thebiogrid.org/​221199/​publication|Virus-host interactome and proteomic survey of PMBCs from COVID-19 patients reveal potential virulence factors influencing SARS-CoV-2 pathogenesis]]** ​ | |  **888800000012** ​ |  **[[https://​doi.org/​10.1101/​2020.03.31.019216|10.1101/​2020.03.31.019216]]** ​ |  Liang Q (2020) ​ | **[[https://​thebiogrid.org/​221199/​publication|Virus-host interactome and proteomic survey of PMBCs from COVID-19 patients reveal potential virulence factors influencing SARS-CoV-2 pathogenesis]]** ​ |
 |  **888800000013** ​ |  **[[https://​doi.org/​10.1101/​2020.04.15.042085|10.1101/​2020.04.15.042085]]** ​ |  Bestle D (2020) ​ | **[[https://​thebiogrid.org/​221402/​publication|TMPRSS2 and furin are both essential for proteolytic activation and spread of SARS-CoV-2 in human airway epithelial cells and provide promising drug targets]]** ​ | |  **888800000013** ​ |  **[[https://​doi.org/​10.1101/​2020.04.15.042085|10.1101/​2020.04.15.042085]]** ​ |  Bestle D (2020) ​ | **[[https://​thebiogrid.org/​221402/​publication|TMPRSS2 and furin are both essential for proteolytic activation and spread of SARS-CoV-2 in human airway epithelial cells and provide promising drug targets]]** ​ |
-|  **888800000014** ​ |  **[[https://​doi.org/​10.1101/​2020.04.09.033233|10.1101/​2020.04.09.033233]]** ​ |  Jin Z (2020) ​ | **[[https://​thebiogrid.org/​221403/​publication|Structural basis for the inhibition of COVID-19 virus main protease by carmofur, an antineoplastic drug]]** ​ | 
-|  **888800000015** ​ |  **[[https://​doi.org/​10.1101/​2020.04.08.032763|10.1101/​2020.04.08.032763]]** ​ |  Yin W (2020) ​ | **[[https://​thebiogrid.org/​221404/​publication|Structural Basis for the Inhibition of the RNA-Dependent RNA Polymerase from SARS-CoV-2 by Remdesivir]]** ​ | 
 |  **888800000016** ​ |  **[[https://​doi.org/​10.1101/​2020.04.14.042010|10.1101/​2020.04.14.042010]]** ​ |  Chi X (2020) ​ | **[[https://​thebiogrid.org/​221405/​publication|Humanized Single Domain Antibodies Neutralize SARS-CoV-2 by Targeting Spike Receptor Binding Domain]]** ​ | |  **888800000016** ​ |  **[[https://​doi.org/​10.1101/​2020.04.14.042010|10.1101/​2020.04.14.042010]]** ​ |  Chi X (2020) ​ | **[[https://​thebiogrid.org/​221405/​publication|Humanized Single Domain Antibodies Neutralize SARS-CoV-2 by Targeting Spike Receptor Binding Domain]]** ​ |
 |  **888800000017** ​ |  **[[https://​doi.org/​10.1101/​2020.04.06.20055475|10.1101/​2020.04.06.20055475]]** ​ |  Ye L (2020) ​ | **[[https://​thebiogrid.org/​221565/​publication|Human monoclonal antibodies block the binding of SARS-CoV-2 spike protein to angiotensin converting enzyme 2 receptor]]** ​ | |  **888800000017** ​ |  **[[https://​doi.org/​10.1101/​2020.04.06.20055475|10.1101/​2020.04.06.20055475]]** ​ |  Ye L (2020) ​ | **[[https://​thebiogrid.org/​221565/​publication|Human monoclonal antibodies block the binding of SARS-CoV-2 spike protein to angiotensin converting enzyme 2 receptor]]** ​ |
Line 40: Line 38:
 |  **888800000033** ​ |  **[[https://​doi.org/​10.1101/​2020.05.01.20077743|10.1101/​2020.05.01.20077743]]** ​ |  Wu Y (2020) ​ | **[[https://​thebiogrid.org/​221836/​publication|A non-competing pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2]]** ​ | |  **888800000033** ​ |  **[[https://​doi.org/​10.1101/​2020.05.01.20077743|10.1101/​2020.05.01.20077743]]** ​ |  Wu Y (2020) ​ | **[[https://​thebiogrid.org/​221836/​publication|A non-competing pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2]]** ​ |
 |  **888800000034** ​ |  **[[https://​doi.org/​10.1101/​2020.05.03.074914|10.1101/​2020.05.03.074914]]** ​ |  Liu X (2020) ​ | **[[https://​thebiogrid.org/​221959/​publication|Neutralizing Antibodies Isolated by a site-directed Screening have Potent Protection on SARS-CoV-2 Infection]]** ​ | |  **888800000034** ​ |  **[[https://​doi.org/​10.1101/​2020.05.03.074914|10.1101/​2020.05.03.074914]]** ​ |  Liu X (2020) ​ | **[[https://​thebiogrid.org/​221959/​publication|Neutralizing Antibodies Isolated by a site-directed Screening have Potent Protection on SARS-CoV-2 Infection]]** ​ |
 +|  **888800000035** ​ |  **[[https://​doi.org/​10.1101/​2020.05.21.109157|10.1101/​2020.05.21.109157]]** ​ |  Lui I (2020) ​ | **[[https://​thebiogrid.org/​222215/​publication|Trimeric SARS-CoV-2 Spike interacts with dimeric ACE2 with limited intra-Spike avidity]]** ​ |
 +|  **888800000036** ​ |  **[[https://​doi.org/​10.1101/​2020.05.21.107870|10.1101/​2020.05.21.107870]]** ​ |  Partridge LJ (2020) ​ | **[[https://​thebiogrid.org/​222216/​publication|Unfractionated heparin potently inhibits the binding of SARS-CoV-2 spike protein to a human cell line]]** ​ |
 +|  **888800000037** ​ |  **[[https://​doi.org/​10.1101/​2020.05.13.092478|10.1101/​2020.05.13.092478]]** ​ |  Chiodo F (2020) ​ | **[[https://​thebiogrid.org/​222217/​publication|Novel ACE2-Independent Carbohydrate-Binding of SARS-CoV-2 Spike Protein to Host Lectins and Lung Microbiota]]** ​ |
 +|  **888800000038** ​ |  **[[https://​doi.org/​10.1101/​2020.05.12.091298|10.1101/​2020.05.12.091298]]** ​ |  Seydoux E (2020) ​ | **[[https://​thebiogrid.org/​222218/​publication|Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual]]** ​ |
 +|  **888800000039** ​ |  **[[https://​doi.org/​10.1101/​2020.05.21.107565|10.1101/​2020.05.21.107565]]** ​ |  Zang J (2020) ​ | **[[https://​thebiogrid.org/​222219/​publication|Immunization with the receptor-binding domain of SARS-CoV-2 elicits antibodies cross-neutralizing SARS-CoV-2 and SARS-CoV without antibody-dependent enhancement]]** ​ |
 +|  **888800000040** ​ |  **[[https://​doi.org/​10.1101/​2020.05.12.092171|10.1101/​2020.05.12.092171]]** ​ |  Zhou X (2020) ​ | **[[https://​thebiogrid.org/​222220/​publication|Structure of SARS-CoV-2 main protease in the apo state reveals the inactive conformation]]** ​ |
 +|  **888800000041** ​ |  **[[https://​doi.org/​10.1101/​2020.06.17.156455|10.1101/​2020.06.17.156455]]** ​ |  Stukalov A (2020) ​ | **[[https://​thebiogrid.org/​222410/​publication|Multi-level proteomics reveals host-perturbation strategies of SARS-CoV-2 and SARS-CoV]]** ​ |
 +|  **888800000042** ​ |  **[[https://​doi.org/​10.1101/​2020.06.05.135921|10.1101/​2020.06.05.135921]]** ​ |  Bertoglio F (2020) ​ | **[[https://​thebiogrid.org/​222602/​publication|SARS-CoV-2 neutralizing human recombinant antibodies selected from pre-pandemic healthy donors binding at RBD-ACE2 interface]]** ​ |
 +|  **888800000043** ​ |  **[[https://​doi.org/​10.1101/​2020.06.05.135699|10.1101/​2020.06.05.135699]]** ​ |  Moustaqil M (2020) ​ | **[[https://​thebiogrid.org/​222603/​publication|SARS-CoV-2 proteases cleave IRF3 and critical modulators of inflammatory pathways (NLRP12 and TAB1): implications for disease presentation across species and the search for reservoir hosts.]]** ​ |
 +|  **888800000044** ​ |  **[[https://​doi.org/​10.1101/​2020.06.17.157982|10.1101/​2020.06.17.157982]]** ​ |  Starr TN (2020) ​ | **[[https://​thebiogrid.org/​222652/​publication|Deep mutational scanning of SARS-CoV-2 receptor binding domain reveals constraints on folding and ACE2 binding]]** ​ |
 +|  **888800000045** ​ |  **[[https://​doi.org/​10.1101/​2020.06.05.134114|10.1101/​2020.06.05.134114]]** ​ |  Daly JL (2020) ​ | **[[https://​thebiogrid.org/​222653/​publication|Neuropilin-1 is a host factor for SARS-CoV-2 infection]]** ​ |
 +|  **888800000046** ​ |  **[[https://​doi.org/​10.1101/​2020.06.17.158121|10.1101/​2020.06.17.158121]]** ​ |  Cubuk J (2020) ​ | **[[https://​thebiogrid.org/​222654/​publication|The SARS-CoV-2 nucleocapsid protein is dynamic, disordered, and phase separates with RNA]]** ​ |
 +|  **888800000047** ​ |  **[[https://​doi.org/​10.1101/​2020.06.09.142794|10.1101/​2020.06.09.142794]]** ​ |  Yang Y (2020) ​ | **[[https://​thebiogrid.org/​222655/​publication|The utility of native MS for understanding the mechanism of action of repurposed therapeutics in COVID-19: heparin as a disruptor of the SARS-CoV-2 interaction with its host cell receptor.]]** ​ |
 +|  **888800000048** ​ |  **[[https://​doi.org/​10.1101/​2020.06.02.130161|10.1101/​2020.06.02.130161]]** ​ |  Hanke L (2020) ​ | **[[https://​thebiogrid.org/​222656/​publication|An alpaca nanobody neutralizes SARS-CoV-2 by blocking receptor interaction]]** ​ |
 +|  **888800000049** ​ |  **[[https://​doi.org/​10.1101/​2020.06.17.156471|10.1101/​2020.06.17.156471]]** ​ |  Conceicao C (2020) ​ | **[[https://​thebiogrid.org/​222704/​publication|The SARS-CoV-2 Spike protein has a broad tropism for mammalian ACE2 proteins]]** ​ |
 +|  **888800000050** ​ |  **[[https://​doi.org/​10.1101/​2020.06.07.138677|10.1101/​2020.06.07.138677]]** ​ |  Luan X (2020) ​ | **[[https://​thebiogrid.org/​222705/​publication|Structure Basis for Inhibition of SARS-CoV-2 by the Feline Drug GC376]]** ​ |
 +|  **888800000051** ​ |  **[[https://​doi.org/​10.1101/​2020.06.02.129098|10.1101/​2020.06.02.129098]]** ​ |  Lv Z (2020) ​ | **[[https://​thebiogrid.org/​222706/​publication|Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody]]** ​ |
 +|  **888800000052** ​ |  **[[https://​doi.org/​10.1101/​2020.06.06.137513|10.1101/​2020.06.06.137513]]** ​ |  Lou Y (2020) ​ | **[[https://​thebiogrid.org/​222707/​publication|Cross-neutralization antibodies against SARS-CoV-2 and RBD mutations from convalescent patient antibody libraries]]** ​ |
 +|  **888800000053** ​ |  **[[https://​doi.org/​10.1101/​2020.05.27.118117|10.1101/​2020.05.27.118117]]** ​ |  Douangamath A (2020) ​ | **[[https://​thebiogrid.org/​222708/​publication|Crystallographic and electrophilic fragment screening of the SARS-CoV-2 main protease]]** ​ |
 +|  **888800000054** ​ |  **[[https://​doi.org/​10.1101/​2020.06.16.155812|10.1101/​2020.06.16.155812]]** ​ |  Li J (2020) ​ | **[[https://​thebiogrid.org/​222709/​publication|Crystal structure of SARS-CoV-2 main protease in complex with a Chinese herb inhibitor shikonin]]** ​ |
 +|  **888800000055** ​ |  **[[https://​doi.org/​10.1101/​2020.06.15.153387|10.1101/​2020.06.15.153387]]** ​ |  Beddingfield B (2020) ​ | **[[https://​thebiogrid.org/​222710/​publication|The Integrin Binding Peptide, ATN-161, as a Novel Therapy for SARS-CoV-2 Infection]]** ​ |
 
covid/unpublished.1591120511.txt.gz · Last modified: 2020/06/02 13:55 by biogridadmin